EXEL vs MRK
EXEL: Exelixis is a profitable oncology company commercializing the multi-kinase inhibitor cabozantinib across multiple cancer indications while advancing a pipeline of next-generation small molecules and antibody-drug conjugates. MRK: Global pharmaceutical and vaccine leader with oncology, infectious disease, and animal health franchises, anchored by blockbuster immunotherapy Keytruda.
Side-by-side fundamentals
| Metric | EXEL | MRK | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $54.98 | $127.47 | |
| Market cap as of 2026-07-23 | $14.0B | $315.3B | |
| P/E as of 2026-07-23 | 16.74 | 35.29 | EXEL lower |
| PEG as of 2026-07-23 | 1.09 | 4.34 | EXEL lower |
| Net margin as of 2026-07-23 | +35.1% | +13.6% | EXEL higher |
| Gross margin as of 2026-07-23 | +96.4% | +78.1% | EXEL higher |
| Operating margin as of 2026-07-23 | +39.4% | +18.2% | EXEL higher |
| ROE as of 2026-07-23 | +40.2% | +17.9% | EXEL higher |
| ROA as of 2026-07-23 | +30.5% | +7.0% | EXEL higher |
| Debt / equity as of 2026-07-23 | 0.00 | 1.07 | EXEL lower |
| Revenue growth (YoY) as of 2026-07-23 | +7.9% | +2.9% | EXEL higher |
| Revenue CAGR (3y) SEC XBRL | +9.5% | +3.1% | EXEL higher |
| Dividend yield as of 2026-07-23 | n/a | +2.7% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-23 | 0.41 | 0.21 | |
| 1-year return as of 2026-07-22 close | +26.8% | +56.2% | MRK higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.